Skip to main content

Disruptive Innovation to Treat Alzheimer’s and Parkinson’s diseases: new target, new patented drug, new therapeutic strategy.

Project description

A chimeric peptide key to the treatment of Alzheimer's and Parkinson's diseases

Alzheimer’s and Parkinson’s diseases are both neurological illnesses caused by damaged brain cells. In the race to find a cure, clinical trials based on anti-amyloid plaques immunotherapies have been unsuccessful. The EU-funded AmInnovation offered a novel solution – AmyP53, a disruptive innovation that can block the very first step of these diseases. The project aimed to de-risk AmyP53 by evaluating its safety in animals. Through the project, the candidate therapeutic agent was synthesised and characterised for its chemical and biological properties and administered in male and female rats via the intravenous and intranasal routes. As expected, all outcomes were outstanding, demonstrating no single toxicity issue, which definitively does open the door for the first-in-human trials very soon.

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Coordinator

AMYPORE
Address
Boulevard Elie Corradi 51
13240 Septemes-les-vallons
France

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000